Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.

Link to article at PubMed

Related Articles

Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.

Pharmacotherapy. 2017 Jul 21;:

Authors: Kufel WD, Devanathan AS, Marx AH, Weber DJ, Daniels LM

Abstract
Over the last decade, the incidence and severity of Clostridium difficile infection (CDI) have significantly increased, leading to a rise in CDI-associated hospitalizations, health care costs, and mortality. Although treatment options exist for CDI, recurrence is frequent following treatment. Furthermore, patients with at least one CDI recurrence are at an increased risk of developing additional recurrences. A novel approach to the prevention of recurrent CDI is the use of monoclonal antibodies directed against the toxins responsible for CDI as an adjunct to antibiotic treatment. Bezlotoxumab, a human monoclonal antibody that binds and neutralizes C. difficile toxin B, is the first therapeutic agent to receive United States Food and Drug Administration approval for the prevention of CDI recurrence. Clinical studies have demonstrated superior efficacy of bezlotoxumab in adults receiving antibiotic therapy for CDI compared with antibiotic therapy alone for the prevention of CDI recurrence. Bezlotoxumab was well tolerated in clinical trials, with the most common adverse effects being nausea, vomiting, fatigue, pyrexia, headache, and diarrhea. The demonstrated efficacy, safety, and characteristics of bezlotoxumab present an advance in prevention of CDI recurrence. This article is protected by copyright. All rights reserved.

PMID: 28730660 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.